IO360° Summit - Who Attends

Who Attends

The program is designed for all size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer.

Biopharma Responsible for

Cancer Immunotherapy
Immuno-Oncology
R&D Innovation & Strategy
Clinical R&D
Business Development
Preclinical and Translational Research

Biomarkers and Companion Dx
Early Stage Collaborations
Clinical Operations
Strategic Partnerships
External R&D
Licensing & Commercial Strategy

Solution Providers

Diagnostic Testing
Biomarkers and Companion Dx
Assay Development
Next Gen Sequencing
mRNA / DNA Nucleic Acid Processing
RNA Sequencing
Cell Analysis/Manufacturing Platforms
Liquid Biopsies

Cancer Genetics
Immune Monitoring
Imaging Services
Flow Cytometry
Data Analysis/Analytics
Laboratory Services
Artificial Intelligence
CROs/Clinical Trial Design

Investment Community Including

Investment Firms
Banks/Financial Institutions
Venture Capital
Private Equity
Foundation Capital
Analysts

Academia & Research Organizations Focusing on

Immuno-Oncology / Cancer Immunotherapy
Oncology
Immunology
Cancer Vaccines
Adoptive T-Cell Therapy
Preclinical & Clinical R&D

Professionals working in immuno-oncology business units will also benefit.

Networking Opportunities

Partnering/One-on-One Meetings:

• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk

Scheduled Networking:

• Scheduled morning and afternooon breaks
• Lunches
• Receptions
• Access to the exhibit hall